Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Super DC Vaccine for preventing solid tumor recurrence
NCT07146672Phase 2Recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Super DC Vaccine in solid tumor, sponsored by Shanghai Cell Therapy Group. Started Jul 2025; status: recruiting.
02
Drugs
Super DC Vaccine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07146672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146672.